Consun Pharmaceutic.Group Logo
KYG2524A1031
A1XAEC
1681.HK

Consun Pharmaceutic.Group

Loading quotes...

Forecast

There is no analyst data available for this company.

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Consun Pharmaceutic.Group has already paid €0.0879 in dividends. The last payout was in October.

Financials

In the last quarter, Consun Pharmaceutic.Group had revenue of €226.99M and net profit of €75.72M
(EUR) June 2026
YoY
Revenue 226.99M -
Gross profit 184.69M -
Net profit 75.72M -
EBITDA 87.29M -

Fundamentals

Metric Value
Market capitalization
€1.45B
Number of shares
839.19M
52-week high/low
€2.22 - €1.40
Dividend yield
4.96%
Dividends TTM
€0.0878
Beta
0.43
P/E ratio
9.31
PEG ratio
0.55
P/B ratio
2.27
P/S ratio
2.99

Company profile

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

Name
Consun Pharmaceutic.Group
CEO
Meng An
Headquarters Guangzhou, gd
China
Website
IPO
12/19/2013
Employees 2,847

Ticker symbols

Exchange Symbol
Hkse
1681.HK
Frankfurt
C1P.F
🍪

Parqet  uses cookies. Learn more